Related Experiment Video
Updated: Jul 4, 2025

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Dalbavancin Use in Persons Who Use Drugs May Increase Adherence Without Increasing Cost
Tiffany A Russo1, Hannah R Ritchie2, Jennifer J Schimmel3,4
1Department of Pharmacy, Middlesex Health, Middletown, CT, USA.
Dalbavancin (DAL) may improve treatment completion for persons who use drugs (PWUD) with infections. While DAL use showed a trend toward higher completion rates, there was no significant difference in financial contribution margins compared to standard treatment.
Area of Science:
- Infectious Diseases
- Pharmacoeconomics
- Health Services Research
Background:
- Dalbavancin (DAL) offers a potential solution to IV access misuse concerns in persons who use drugs (PWUD) undergoing outpatient infection treatment.
- Hesitancy in DAL adoption stems from high costs and insurance reimbursement challenges.
- This study evaluates the financial impact and treatment completion rates associated with DAL use.
Purpose of the Study:
- To determine the financial impact of Dalbavancin (DAL) in persons who use drugs (PWUD).
- To assess the effect of DAL on healthcare utilization and treatment completion rates.
- To compare the cost-effectiveness of DAL versus traditional treatment regimens.
Main Methods:
- Retrospective cohort study comparing patients who received DAL with a control group.
- Analysis of actual measured costs and healthcare utilization data.
- Evaluation of treatment completion rates for Staphylococcus aureus bacteremia.
Main Results:
- Twenty-nine PWUD received DAL between June 2020 and January 2022.
- Treatment completion was observed in 66% of patients receiving DAL versus 55% in the control group.
- The contribution margin for DAL was $7180, compared to $6655 for the control group, a non-statistically significant difference (P=0.47).
Conclusions:
- Dalbavancin (DAL) use in persons who use drugs (PWUD) may enhance treatment completion rates for infections.
- No statistically significant difference in contribution margins was found between DAL and standard treatment.
- DAL presents a potential option for improving adherence in specific patient populations.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drug Therapy
Antianxiety Medications
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

